Predictive Signature of Benralizumab Response

PHASE4RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions
Asthma; EosinophilicSevere Asthma
Interventions
DRUG

Benralizumab Prefilled Syringe

Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.

Trial Locations (20)

Unknown

RECRUITING

Centre hospitalier Intercommunal Aix-en-Provence, Aix-en-Provence

RECRUITING

CHU Angers, Angers

RECRUITING

CHU Bordeaux, Bordeaux

RECRUITING

CHRU Brest, Brest

RECRUITING

CHU Dijon, Dijon

RECRUITING

CHU Grenoble, Grenoble

RECRUITING

Hôpital Bicêtre - AP-HP, Le Kremlin-Bicêtre

WITHDRAWN

CH Mans, Le Mans

WITHDRAWN

CHU Lille, Lille

RECRUITING

Hospices Civils de Lyon, Lyon

NOT_YET_RECRUITING

Assistance Publique des Hôpitaux de Marseille, Marseille

WITHDRAWN

CHU Montpellier, Montpellier

RECRUITING

CHU Nantes, Nantes

RECRUITING

CHR Orléans, Orléans

RECRUITING

Hôpital Bichat - AP-HP, Paris

WITHDRAWN

CHU Rouen, Rouen

RECRUITING

CHU Strasbourg, Strasbourg

RECRUITING

Hôpital FOCH, Suresnes

RECRUITING

CHU Toulouse, Toulouse

RECRUITING

Médipôle Hôpital Mutualiste de Villeurbanne, Villeurbanne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Ministère de la Santé - France

UNKNOWN

lead

Nantes University Hospital

OTHER